Compared to placebo, high-dose recombinant human erythropoietin within 2 days of life does not improve neurodevelopmental outcomes for preterm infants.

Availability of numerous biosimilars has rendered low-cost options for patients, therefore, increased adoption rates for EPO drugs particularly in developing regions, which boosts the market growth.

CLL, chronic lymphocytic leukemia; EPO, erythropoietin ... and treatment with recombinant human erythropoietins has been shown to reduce transfusion rates and increase hemoglobin (Hb) response ...

Because low plasma erythropoietin levels are present in anemia of prematurity, it has been theorized that enhancing erythropoiesis with recombinant erythropoietin (rhEPO) would reduce the need for ...

Erythropoietin (EPO) is a hormone that increases red blood cell production, enhancing endurance performance by improving oxygen delivery to muscles, making it a popular choice for athletes. Brisbane's ...

SIA noted the B sample analysis was an “atypical finding (ATF) for recombinant EPO”. “The relevant rules require a WADA-accredited laboratory to obtain a second opinion from an expert ... an ATF is ...

Recombinant glycoproteins produced by mammalian cell lines are currently being developed as therapeutics for a spectrum of diseases. Chinese hamster ovary (CHO) cells are widely used for this ...

Recombinant human erythropoietin (rEpo) is neuroprotective in neonatal models of hypoxic-ischemic brain injury. However, the optimal rEpo dose, dosing interval, and number of doses for reducing ...